Ofatumumab versus Teriflunomide in Multiple Sclerosis

2020663 citationsJournal Articlebronze Open Access

Authors

Stephen L. Hauser · University of California, San Francisco

Amit Bar‐Or · Multiple Sclerosis Research Institute

Jeffrey Cohen · Cleveland Clinic

Gıancarlo Comı · Multiple Sclerosis Research Institute

Jorge Correale · Multiple Sclerosis Research Institute

Patricia K. Coyle · Multiple Sclerosis Research Institute

Anne H. Cross

Abstract

Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).

Topics & Keywords

Multiple Sclerosis Research Studies Cytokine Signaling Pathways and Interactions Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 6, pp. 546-557

DOI: 10.1056/nejmoa1917246

Field-Weighted Citation Impact: 48.45